BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 27673280)

  • 41. Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Swoboda R; Kulagin A; Labussière-Wallet H; Rovira M; Blaise D; Vydra J; Yakoub-Agha I; Choi G; Reményi P; Koc Y; Sanz J; Ciceri F; Mohty M
    Bone Marrow Transplant; 2023 May; 58(5):552-557. PubMed ID: 36823454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
    Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
    Abdelaty MM; Gawaly A; Fathy GM; Kabbash I; Taha A
    J Egypt Natl Canc Inst; 2020 Jun; 32(1):28. PubMed ID: 32537680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Kharfan-Dabaja MA; Labopin M; Bazarbachi A; Socie G; Kroeger N; Blaise D; Veelken H; Bermudez A; Or R; Lioure B; Beelen D; Fegueux N; Hamladji RM; Nagler A; Mohty M
    Leuk Res; 2015 Sep; 39(9):933-7. PubMed ID: 26003666
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.
    Duléry R; Ménard AL; Chantepie S; El-Cheikh J; François S; Delage J; Giannotti F; Ruggeri A; Brissot E; Battipaglia G; Malard F; Belhocine R; Sestili S; Vekhoff A; Delhommeau F; Reman O; Legrand O; Labopin M; Rubio MT; Mohty M
    Biol Blood Marrow Transplant; 2018 May; 24(5):1013-1021. PubMed ID: 29337223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.
    Eom KS; Shin SH; Yoon JH; Yahng SA; Lee SE; Cho BS; Kim YJ; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Park CW; Lee S
    Am J Hematol; 2013 Aug; 88(8):634-41. PubMed ID: 23620000
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.
    Eder S; Labopin M; Finke J; Bunjes D; Olivieri A; Santarone S; Rambaldi A; Kanz L; Messina G; Mohty M; Nagler A
    Bone Marrow Transplant; 2017 Feb; 52(2):238-244. PubMed ID: 27643865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission.
    Han LJ; Wang Y; Fan ZP; Huang F; Zhou J; Fu YW; Qu H; Xuan L; Xu N; Ye JY; Bian ZL; Song YP; Huang XJ; Liu QF
    Br J Haematol; 2017 Oct; 179(1):120-130. PubMed ID: 28737249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
    Ferrá C; Sanz J; de la Cámara R; Sanz G; Bermúdez A; Valcárcel D; Rovira M; Serrano D; Caballero D; Espigado I; Morgades M; Heras I; Solano C; Duarte R; Barrenetxea C; García-Noblejas A; Díez-Martin JL; Iriondo A; Carreras E; Sierra J; Sanz MA; Ribera JM;
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):957-66. PubMed ID: 20144909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
    Cho BS; Lee S; Kim YJ; Chung NG; Eom KS; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Kim CC
    Leukemia; 2009 Oct; 23(10):1763-70. PubMed ID: 19440217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
    Marks DI; Forman SJ; Blume KG; Pérez WS; Weisdorf DJ; Keating A; Gale RP; Cairo MS; Copelan EA; Horan JT; Lazarus HM; Litzow MR; McCarthy PL; Schultz KR; Smith DD; Trigg ME; Zhang MJ; Horowitz MM
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):438-53. PubMed ID: 16545728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Shimoni A; Labopin M; Savani B; Byrne M; Volin L; Finke J; Niederwieser D; Ehninger G; Blaise D; Beelen D; Tabrizi R; Sengeloev H; Ganser A; Cornelissen JJ; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2251-2260. PubMed ID: 31271887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children.
    Woolfrey AE; Anasetti C; Storer B; Doney K; Milner LA; Sievers EL; Carpenter P; Martin P; Petersdorf E; Appelbaum FR; Hansen JA; Sanders JE
    Blood; 2002 Mar; 99(6):2002-8. PubMed ID: 11877272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Poiré X; Labopin M; Maertens J; Yakoub-Agha I; Blaise D; Ifrah N; Socié G; Gedde-Dhal T; Schaap N; Cornelissen JJ; Vigouroux S; Sanz J; Michaux L; Esteve J; Mohty M; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):20. PubMed ID: 28100265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia.
    Corker E; Astwood E; Williams J; Vora A
    Br J Haematol; 2012 Oct; 159(1):104-6. PubMed ID: 22804487
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
    Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A
    J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.